Sequencing analysis of CD4 positive CAR T cells pre treated with dexamethasone

Our findings indicate that following multiple rounds of tumor cell stimulation, CD4+ CAR T cells demonstrated robust proliferation capabilities with reduced apoptosis rates, while also maintaining their effector phenotype. To further optimize the functionality of CD4+ CAR T cells, we implemented a low-dose decitabine pretreatment strategy for CAR T cells (referred to as dCAR T) during the CAR T cell preparation process.

After three rounds of in vitro tumor cell stimulation, dCAR T cells exhibit sustained anti-tumor efficacy and proliferation capacity. Analysis of bulk RNA sequencing data validates the enhanced effector phenotype and proliferation potential of dCAR T cells relative to conventional CAR T cells. These findings indicate that pretreatment with decitabine may modulate the transcriptional profile of CAR T cells.